Abstract
Overview
Introduction
In 2008, the six tumor types covered in this report are forecast to account
for over 666,000 new cases of cancer, obviously representing an enormous
market potential. However, it is the higher-incidence tumor types that
continue to attract drug developers, with lower-incidence cancers potentially
suffering due to unfulfilled unmet needs via a lack of R&D activity.
Scope
- Examination of the solid cancer pipeline with in-depth clinical and
commercial profiles of Phase III candidates for six tumor types
- Seven major pharmaceutical market sales forecasts for Phase III pipeline
products through to 2017 with product-specific assumptions
- Segmentation and analysis of the current solid tumor pipeline by
developmental phase, drug class and indication for six tumor types
- Insight and analysis of market potential including commercial opportunity,
epidemiology, commonalities across cancers and discussion of unmet needs
Report Highlights
A low level of interest from drug developers means unmet needs in the SCLC,
mesothelioma, primary brain and thyroid cancer markets are likely to remain
unfulfilled. Drug developers should realize that despite being low-incidence
tumor types, high unmet needs could result in significant financial rewards
and a foothold in the market to build upon.
Erbitux (cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono) shows the most
promise in the current NSCLC pipeline. Recent clinical trial results mean
Erbitux may become a viable option in the first-line treatment of NSCLC,
particularly for those patients ineligible for Avastin (bevacizumab;
Genentech/Roche) therapy.
Vectibix (panitumumab; Amgen) and zalutumumab (HuMax-EGFR; Genmab/Medarex)
show great promise to compete with Erbitux in the head and neck cancer market,
particularly due to potential toxicity advantages that fully human monoclonal
antibodies may have.
Reasons to Purchase
- Identify key drugs and companies within the oncology pipeline based on
sales forecasts to 2017 and Datamonitor drug assessment
- Characterize unmet need and poorly served markets within oncology and
assess the potential for pipeline products to provide satisfaction
- Assess the shifting oncology market dynamic and how future treatment of
solid tumors will incorporate pipeline products
| 
View Cart
